Revascularization Strategy of Multivessel Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator (RESCUE-SHOCK)
Primary Purpose
Cardiogenic Shock, Acute Myocardial Infarction, Multi Vessel Coronary Artery Disease
Status
Recruiting
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Culprit lesion only PCI
Immediate multi-vessel PCI
Sponsored by
About this trial
This is an interventional treatment trial for Cardiogenic Shock
Eligibility Criteria
Inclusion Criteria:
- Subject must be at least 19 years of age
- Patients presented with AMI (ST-segment elevation MI [STEMI] or non-ST-segment elevation MI [NSTEMI]) complicated by CS (SCAI Shock classification C, D or E) who requiring VA-ECMO.
- Target lesions amenable for planned primary PCI by operators' decision
- Patients with multi-vessel disease
Exclusion Criteria:
- Other causes of shock (hypovolemia, sepsis, obstructive shock).
- Shock due to mechanical complication to MI (rupture of papillary muscle, the ventricular septum, or free wall).
- Unwitnessed out of hospital cardiac arrest with persistent Glasgow coma scale <8 after the return of spontaneous circulation.
- Patients with single-vessel disease (Patients with single-vessel disease will be enrolled in the RESCUE-SHOCK registry)
- Onset of shock >24 hours.
- Known heparin intolerance.
- Other severe concomitant disease with limited life expectancy < 6 months
- Pregnancy or breast feeding
- Do not resuscitate wish
Sites / Locations
- Samsung Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Culprit-lesion only PCI arm
Immediate multi-vesesl PCI arm
Arm Description
Patients will receive culprit-lesion only PCI.
Patients will receive immediate multi-vessel PCI.
Outcomes
Primary Outcome Measures
Rates of all-cause mortality or advanced heart failure requiring cardiac replacement therapy
all-cause mortality or requiring left ventricular assisted device (LVAD) insertion or heart transplantation)
Secondary Outcome Measures
Rates of In-hospital mortality
Death by any cause in hospital
Rates of In-hospital cardiac mortality
Death by cardiac cause in hospital
Rates of VA-ECMO weaning success
Successful weaning of VA-ECMO was defined as successful removal of VA-ECMO and not requiring further mechanical support because of recurring cardiogenic shock over the following 48 hours.
Time to VA-ECMO weaning
Time from VA-ECMO insertion to VA-ECMO weaning
Rates of critical limb ischemia after successful VA-ECMO weaning
Critical limb ischemia is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity. (Rutherford classification 4, 5, or 6)
Cerebral Performance Category (CPC) 3-5 at discharge
Neurologic performance scale at discharge
Length of intensive-care unit (ICU) stay
ICU stay day
Total procedural time
Procedural time (minutes)
Total amount of contrast use
Contrast use (cc)
Rates of all-cause mortality
Death by any cause
Rates of cardiac mortality
Death by cardiac cause
Requirement of cardiac replacement therapy
LVAD insertion or heart transplantation
Requirement of renal replacement therapy
Continuous renal replacement therapy, hemodialysis, or peritoneal dialysis
Rates of myocardial infarction (MI)
spontaneous MI during follow-up
Rates of MI related to culprit vessel
MI related to culprit vessel during follow-up
Rates of MI related to non-culprit vessel
MI related to non-culprit vessel during follow-up
Rates of stent thrombosis
Academic Research Consortium (ARC)-defined definite or probable stent thrombosis
Rates of Re-hospitalization due to heart failure
Re-hospitalization due to heart failure during follow-up
Rates of Re-hospitalization due to any cause
Re-hospitalization due to any cause during follow-up
Rates of target-lesion revascularization (TLR)
TLR during follow-up
Rates of target-vessel revascularization (TVR)
TVR during follow-up
Rates of repeat revascularization
Repeat revascularization during follow-up
Rates of cerebrovascular accident
Cerebrovascular accident during follow-up
Rates of bleeding
Bleeding ARC [BARC] type 2, 3, or 5
Rates of major bleeding
(BARC type 3 or 5
Full Information
NCT ID
NCT05527717
First Posted
August 27, 2022
Last Updated
December 19, 2022
Sponsor
Samsung Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT05527717
Brief Title
Revascularization Strategy of Multivessel Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator
Acronym
RESCUE-SHOCK
Official Title
REvaSCUlarization StratEgy of Multivessel Coronary Artery Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic SHOCK Undergoing Veno-arterial Extracorporeal Membrane Oxygenator: Randomized-Controlled Trial (RESCUE-SHOCK)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 16, 2022 (Actual)
Primary Completion Date
December 31, 2027 (Anticipated)
Study Completion Date
December 31, 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Samsung Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).
Detailed Description
Cardiogenic shock (CS) is a fatal complication of acute myocardial infarction (AMI). Until now, in this setting, it has been well-known that early revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) was associated with improved clinical outcomes although the rate of mortality remains still high in the mechanical circulatory support (MCS) era. In real-world practice, since clinically significant non-infarct related artery (non-IRA) stenosis or occlusion in addition to an IRA can be found in 70% to 80% of patients with AMI complicated by CS, the decision of revascularization strategy is a crucial issue to improve clinical outcomes in CS patients with multivessel disease. The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) and the 2017 European Society of Cardiology (ESC) guidelines recommend considering PCI of severe stenosis in non-IRA during a primary procedure to improve overall myocardial perfusion and hemodynamic stability for patients with AMI and CS. However, the CULPRIT-SHOCK trial, which is the largest randomized trial in CS, demonstrated the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was higher in the immediate multi-vessel PCI than in the culprit lesion-only PCI group. In this regard, the recently updated guidelines do not recommend the routine non-IRA revascularization during primary PCI and it should be considered in selected cases in which there is a very severe flow-limiting non-IRA stenosis irrigating a large myocardial area. Nevertheless, there is still some unsolved issue regarding the role of non-IRA revascularization in AMI patients with CS. Majority of enrolled patients in the CULPRIT-SHOCK trial might have a mild form of CS (median systolic blood pressure of 100) and few patients received MCS devices (28.3% of study population). Furthermore, the mortality benefits of culprit-only PCI were attenuated at 1-year follow-up with an increased risk of repeat revascularization and hospitalization for heart failure. In contrast to the CULPRIT-SHOCK trial, the recent large United State registry from National Cardiovascular Data Registry demonstrated that the benefits of multi-vessel PCI in patients with non-ST-segment elevation MI and CS was more pronounced in those requiring MCS. In addition, recent data from the Korea Acute Myocardial Infarction National Health Registry showed that multivessel PCI was associated with a lower risk of all-cause death than culprit-only PCI, suggesting possible benefit of nonculprit lesion revascularization during the index hospitalization on long-term clinical outcomes.
Therefore, the current randomized trial sought to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with advanced form of CS patients who requiring veno-arterial extracorporeal membrane oxygenator (VA-ECMO).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiogenic Shock, Acute Myocardial Infarction, Multi Vessel Coronary Artery Disease, Extracorporeal Membrane Oxygenation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Prospective, open-label, two-arm, randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
560 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Culprit-lesion only PCI arm
Arm Type
Active Comparator
Arm Description
Patients will receive culprit-lesion only PCI.
Arm Title
Immediate multi-vesesl PCI arm
Arm Type
Experimental
Arm Description
Patients will receive immediate multi-vessel PCI.
Intervention Type
Procedure
Intervention Name(s)
Culprit lesion only PCI
Intervention Description
Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.
This group will be taken culprit-lesion only PCI during primary PCI.
Intervention Type
Procedure
Intervention Name(s)
Immediate multi-vessel PCI
Intervention Description
Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.
This group will be taken immediate multi-vesesl PCI during primary PCI.
Primary Outcome Measure Information:
Title
Rates of all-cause mortality or advanced heart failure requiring cardiac replacement therapy
Description
all-cause mortality or requiring left ventricular assisted device (LVAD) insertion or heart transplantation)
Time Frame
90 days after primary PCI
Secondary Outcome Measure Information:
Title
Rates of In-hospital mortality
Description
Death by any cause in hospital
Time Frame
Up to 30 days
Title
Rates of In-hospital cardiac mortality
Description
Death by cardiac cause in hospital
Time Frame
Up to 30 days
Title
Rates of VA-ECMO weaning success
Description
Successful weaning of VA-ECMO was defined as successful removal of VA-ECMO and not requiring further mechanical support because of recurring cardiogenic shock over the following 48 hours.
Time Frame
Up to 30 days
Title
Time to VA-ECMO weaning
Description
Time from VA-ECMO insertion to VA-ECMO weaning
Time Frame
Up to 30 days
Title
Rates of critical limb ischemia after successful VA-ECMO weaning
Description
Critical limb ischemia is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity. (Rutherford classification 4, 5, or 6)
Time Frame
Up to 30 days
Title
Cerebral Performance Category (CPC) 3-5 at discharge
Description
Neurologic performance scale at discharge
Time Frame
Up to 30 days
Title
Length of intensive-care unit (ICU) stay
Description
ICU stay day
Time Frame
Up to 30 days
Title
Total procedural time
Description
Procedural time (minutes)
Time Frame
Immediate after the index procedure
Title
Total amount of contrast use
Description
Contrast use (cc)
Time Frame
Immediate after the index procedure
Title
Rates of all-cause mortality
Description
Death by any cause
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of cardiac mortality
Description
Death by cardiac cause
Time Frame
90 Days and 12 months after primary PCI
Title
Requirement of cardiac replacement therapy
Description
LVAD insertion or heart transplantation
Time Frame
90 Days and 12 months after primary PCI
Title
Requirement of renal replacement therapy
Description
Continuous renal replacement therapy, hemodialysis, or peritoneal dialysis
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of myocardial infarction (MI)
Description
spontaneous MI during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of MI related to culprit vessel
Description
MI related to culprit vessel during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of MI related to non-culprit vessel
Description
MI related to non-culprit vessel during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of stent thrombosis
Description
Academic Research Consortium (ARC)-defined definite or probable stent thrombosis
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of Re-hospitalization due to heart failure
Description
Re-hospitalization due to heart failure during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of Re-hospitalization due to any cause
Description
Re-hospitalization due to any cause during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of target-lesion revascularization (TLR)
Description
TLR during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of target-vessel revascularization (TVR)
Description
TVR during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of repeat revascularization
Description
Repeat revascularization during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of cerebrovascular accident
Description
Cerebrovascular accident during follow-up
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of bleeding
Description
Bleeding ARC [BARC] type 2, 3, or 5
Time Frame
90 Days and 12 months after primary PCI
Title
Rates of major bleeding
Description
(BARC type 3 or 5
Time Frame
90 Days and 12 months after primary PCI
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject must be at least 19 years of age
Patients presented with AMI (ST-segment elevation MI [STEMI] or non-ST-segment elevation MI [NSTEMI]) complicated by CS (SCAI Shock classification C, D or E) who requiring VA-ECMO.
Target lesions amenable for planned primary PCI by operators' decision
Patients with multi-vessel disease
Exclusion Criteria:
Other causes of shock (hypovolemia, sepsis, obstructive shock).
Shock due to mechanical complication to MI (rupture of papillary muscle, the ventricular septum, or free wall).
Unwitnessed out of hospital cardiac arrest with persistent Glasgow coma scale <8 after the return of spontaneous circulation.
Patients with single-vessel disease (Patients with single-vessel disease will be enrolled in the RESCUE-SHOCK registry)
Onset of shock >24 hours.
Known heparin intolerance.
Other severe concomitant disease with limited life expectancy < 6 months
Pregnancy or breast feeding
Do not resuscitate wish
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeong Hoon Yang, MD
Phone
82-2-3410-3419
Email
jhysmc@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ki Hong Choi, MD
Phone
82-2-3410-6653
Email
cardiokh@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeong Hoon Yang, MD
Organizational Affiliation
Samsung Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeong Hoon Yang, MD
Phone
82-2-3410-3419
Email
jhysmc@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Revascularization Strategy of Multivessel Disease for Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator
We'll reach out to this number within 24 hrs